BioXcel Therapeutics Inc (BTAI)
2.125
0.00 (0.00%)
USD |
NASDAQ |
May 15, 14:41
BioXcel Therapeutics Cash from Operations (Quarterly): -17.71M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -17.71M |
| December 31, 2023 | -26.86M |
| September 30, 2023 | -37.58M |
| June 30, 2023 | -38.21M |
| March 31, 2023 | -52.35M |
| December 31, 2022 | -38.64M |
| September 30, 2022 | -31.19M |
| June 30, 2022 | -33.10M |
| March 31, 2022 | -32.41M |
| December 31, 2021 | -19.93M |
| September 30, 2021 | -20.20M |
| June 30, 2021 | -22.38M |
| March 31, 2021 | -19.64M |
| December 31, 2020 | -20.27M |
| September 30, 2020 | -19.10M |
| Date | Value |
|---|---|
| June 30, 2020 | -14.82M |
| March 31, 2020 | -12.16M |
| December 31, 2019 | -7.919M |
| September 30, 2019 | -7.485M |
| June 30, 2019 | -6.027M |
| March 31, 2019 | -5.67M |
| December 31, 2018 | -4.341M |
| September 30, 2018 | -3.186M |
| June 30, 2018 | -4.97M |
| March 31, 2018 | -1.012M |
| December 31, 2017 | -1.098M |
| September 30, 2017 | -0.322M |
| June 30, 2017 | -0.345M |
| March 31, 2017 | -0.431M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-52.35M
Minimum
Mar 2023
-6.027M
Maximum
Jun 2019
-23.90M
Average
-20.24M
Median
Cash from Operations (Quarterly) Benchmarks
| Cormedix Inc | -17.31M |
| Bristol-Myers Squibb Co | 2.834B |
| Amicus Therapeutics Inc | -29.70M |
| Insmed Inc | -184.04M |
| InfuSystems Holdings Inc | 0.377M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 26.63M |
| Free Cash Flow | -120.36M |
| Free Cash Flow Per Share (Quarterly) | -0.5736 |
| Free Cash Flow to Equity (Quarterly) | -18.74M |
| Free Cash Flow Yield | -190.8% |